4 / 9
Page 12
Biol Med Case Rep 2017 | Volume 1 Issue 2
allied
academies
November 06-07, 2017 | New Orleans, USA
Nanomedicine & Healthcare
Global Meet on
O
ne of the major advantages of nanobiotechnology is
its unique multifunctional characteristics. Targeted
delivery of drug incorporated nanoparticles, through
conjugation of tumor-specific cell surface markers, such as
tumor-specific antibodies or ligands, which can enhance
the efficacy of the anticancer drug and reduce the side
effects and enable personalization for precision medicines.
Additionally, multifunctional characteristics of the nano-
carrier system would allow for simultaneous imaging,
targeted drug delivery and monitoring (Theranostics). A
summary of recent progress in nanotechnology as it relates
specifically to nanoparticles and anticancer drug delivery
will be reviewed. Nano nutraceuticals using combination of
various natural products provide a great potential in diseases
prevention. Additionally, various nanomedicine approaches
for the detection and treatment of various types of organ
specific delivery, vascular targeting, and vaccine will be
briefly discussed. Highlight the role of nanobiotechnology
and other enabling technologies in the followings: Nano
synthesis and assembly of various platforms for targeted
delivery, nanobiotechnology in improving efficacy and safety
and enabling precision treatment and personalization.
Speaker Biography
Shaker A Mousa is currently an endowed tenure Professor and Executive Vice President
and Chairman of the Pharmaceutical Research Institute and Vice Provost for Research
at ACPHS. Prior to his academic career, he has held a Senior Scientist and Fellow at The
DuPont Pharmaceutical Company for 17 years, where he contributed to the discovery
and development of several FDA approved and globally marketed diagnostics and
therapeutics. He holds over 350 US and International Patents discovering novel anti-
angiogenesis strategies, antithrombotic, anti-integrin, anti-cancer, and non-invasive
diagnostic imaging approaches employing various nanotechnology platforms. He has
published more than 1,000 journal articles, book chapters, patents, and books as
Editor and author. He is a Member of several NIH study sections, Editor-In-Chief, and
on the Editorial Board of several high impact journals. His research has focused on
diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular
and cardiovascular diseases.
e:
shaker.mousa@acphs.eduShaker A Mousa
Albany College of Pharmacy and Health Science, USA
Impact of nanobiotechnology on the future of medicine (nanomedicine): The road
toward precision medicine